-
Diagnostics World News | A significantly heightened risk of breast cancer has two well-known culprits—mutations to the tumor suppressor genes BRCA1 and BRCA2—but more than 40% of the time they are black-box “variants of uncertain significance.” Using a new data-sharing innovation known as federated analysis, however, an international team of researchers has categorized 16 of these uncertain variants as benign or likely benign so their carriers may be able to have their clinical risk of disease managed properly and avoid the risk of invasive and irrevocable surgeries.
Jun 14, 2022
-
Diagnostics World News | Novel network analysis technology that uses only 10 minutes of resting state electrophysiological recordings has been shown to localize seizure onset brain regions and predict seizure outcomes in epilepsy patients.
Jun 8, 2022
-
Diagnostics World News | At the Bio-IT World Conference & Expo last month, several sessions explored ways AI is transforming oncology diagnosis, research, and care delivery. Speakers from the National Cancer Institute, Tempus Labs, The Ohio State University, IQVIA, Pangaea Data, University of Illinois Cancer Center, Stable Solutions and more discussed how far we’ve come, and where our next challenges lie.
Jun 7, 2022
-
Diagnostics World News | The U.S. Food and Drug Administration’s Center for Devices and Radiological Health this week announced that it will start accepting all non-COVID in vitro diagnostic pre-submissions starting June 1, 2022.
Jun 3, 2022
-
Diagnostics World News | Innovative Practices Award | Extracting high-quality data from clinical records can be time-consuming and costly, primarily when manual abstractors are tasked with mining complex, unstructured, and lengthy documents. That’s why the scientists at Guardant Health and Linguamatics, an IQVIA company, launched a real-world evidence database called GuardantINFORM. The platform was named one of the 2022 Bio-IT World Innovative Practices award winners.
Jun 2, 2022
-
Diagnostics World News | Crosscope and Farcast Bioscience created OrionAI–an artificially intelligent (AI) diagnostic assistant for tumor histological examination. Crosscope developed the AI-enabled digital pathology platform and proprietary algorithms, while Farscape Bioscience created the histoculture platform that preserves entire human tumor microenvironments. OrionAI increases diagnostic speed and lowers misdiagnosis rates of head and neck squamous cell carcinoma, a highly prevalent disease worldwide.
May 31, 2022
-
Diagnostics World | This week Illumina announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight Oncology (TSO) Comprehensive (EU) test. This single test kit, recently launched across Europe, assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer.
May 27, 2022